Autolus Therapeutics plc · NASDAQ (us_market)
Healthcare · Biotechnology · United Kingdom
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-06$2.00 RISE2026-03-27$1.21 PEAK2026-05-29$1.87 143d | -39.5% 80d | Missed | Missed | — | — | +54.5% 63d | Missed |
DROP2026-01-06$2.00 RISE2026-02-05$1.32 PEAK2026-02-24$1.82 49d | -34.0% 30d | Missed | Missed | — | — | +37.9% 19d | Missed |
DROP2025-07-23$2.68 RISE2025-11-21$1.23 PEAK2026-01-06$2.00 167d | -54.1% 121d | Missed | Missed | — | — | +62.6% 46d | Missed |
DROP2025-07-23$2.68 RISE2025-11-20$1.23 PEAK2026-01-06$2.00 167d | -54.1% 120d | Missed | Missed | — | — | +62.6% 47d | Missed |
DROP2025-07-23$2.68 RISE2025-09-17$1.27 PEAK2025-10-08$1.76 77d | -52.6% 56d | Missed | Missed | — | — | +38.6% 21d | Missed |
DROP2024-11-29$3.32 RISE2025-04-10$1.14 PEAK2025-07-09$2.47 222d | -65.7% 132d | Missed | Missed | — | — | +116.7% 90d | Missed |
DROP2024-07-31$4.69 RISE2024-09-25$3.45 PEAK2024-10-18$4.80 79d | -26.4% 56d | Missed | Missed | — | — | +39.1% 23d | Missed |
DROP2024-04-05$5.60 RISE2024-08-14$3.59 PEAK2024-10-18$4.80 196d | -35.9% 131d | Missed | Missed | — | — | +33.7% 65d | Missed |
DROP2024-02-16$6.83 RISE2024-06-27$3.33 PEAK2024-07-31$4.69 166d | -51.2% 132d | Missed | Missed | — | — | +40.8% 34d | Missed |
DROP2024-01-11$7.29 RISE2024-04-30$3.68 PEAK2024-07-26$4.67 197d | -49.5% 110d | Missed | Missed | — | — | +26.9% 87d | Missed |
DROP2024-01-11$7.29 RISE2024-03-07$5.39 PEAK2024-03-20$6.55 69d | -26.1% 56d | Missed | Missed | — | — | +21.5% 13d | Missed |
DROP2024-01-11$7.29 RISE2024-01-23$5.52 PEAK2024-02-14$7.25 34d | -24.3% 12d | Missed | Missed | — | — | +31.3% 22d | Missed |
DROP2023-08-23$3.36 RISE2023-10-03$2.13 PEAK2023-12-27$6.63 126d | -36.6% 41d | Missed | Missed | — | — | +211.3% 85d | Missed |
DROP2023-07-31$3.23 RISE2023-08-16$2.64 PEAK2023-11-03$4.09 95d | -18.3% 16d | Missed | Missed | — | — | +54.9% 79d | Missed |
DROP2023-05-30$3.21 RISE2023-06-29$2.28 PEAK2023-08-23$3.36 85d | -29.0% 30d | Missed | Missed | — | — | +47.4% 55d | Missed |
1–15 / 31 1 / 3 | |||||||
European equities traded in the US as American depositary receipts were trending slightly lower late
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
European equities traded in the US as American depositary receipts were trending slightly higher lat
European equities traded in the US as American depositary receipts were tracking marginally lower la
European equities traded in the US as American depositary receipts were trending lower late Tuesday
European equities traded in the US as American depositary receipts were heading higher late Monday m
European equities traded in the US as American depositary receipts were heading higher late Monday m
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
Autolus Therapeutics PLC (AUTL) reports significant revenue growth and operational milestones, while navigating financial losses and market expansion hurdles.
Autolus Therapeutics PLC (AUTL) reports significant revenue growth and operational milestones, while navigating financial losses and market expansion hurdles.
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call May 14, 2026 8:30 AM EDTCompany ParticipantsAmanda Cray - Executive Director of Investor Relations...
Presentation Operator MessageOperator Good day, everyone, and welcome to Autolus Therapeutics First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that...
2026-05-14. The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2026 Q1 earnings call.
European equities traded in the US as American depositary receipts were moving higher late Thursday
European equities traded in the US as American depositary receipts were moving higher late Thursday
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy. Chief Executive Officer Dr. Christian Itin said the company h
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy. Chief Executive Officer Dr. Christian Itin said the company h
HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.
Autolus Therapeutics Q1 2026 revenue of $26.2M narrowly missed estimates, but achieved first-ever positive gross margin. Stock fell 3.5% pre-market amid cautious full-year guidance.
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL an
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AUTL | +27.21% | +11.98% | -6.03% | +6.86% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +24.24% | +17.69% | -2.59% | -5.83% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 2.30M | $3.17M | 0.00% | Trimmed-26.0% | 2026-03-31 |
| Citadel | multi-strat | 427.0K | $589.24K | 0.00% | Added+39.8% | 2026-03-31 |
| StateStreet | passive | 83.5K | $115.28K | 0.00% | Added+2.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -0.23 | — | — |
| 2026-05-14 | -0.26 | -0.27 | -4.20% |
| 2026-03-27 | -0.27 | -0.34 | -28.00% |
| 2025-11-12 | -0.23 | -0.30 | -32.84% |
| 2025-08-12 | -0.23 | -0.18 | +23.37% |
| 2025-05-08 | -0.25 | -0.26 | -4.19% |
| 2025-03-20 | -0.24 | -0.09 | +62.87% |
| 2024-11-12 | -0.22 | -0.31 | -41.99% |
| 2024-08-08 | -0.21 | -0.22 | -7.00% |
| 2024-05-17 | -0.14 | -0.24 | -76.47% |
| 2024-03-14 | -0.26 | -0.45 | -75.62% |
| 2023-11-02 | -0.25 | -0.26 | -4.00% |
| 2023-08-03 | -0.22 | -0.26 | -15.92% |
| 2023-05-04 | -0.27 | -0.23 | +14.81% |
| 2023-03-07 | -0.28 | -0.23 | +18.50% |
| 2022-11-03 | -0.46 | -0.47 | -2.61% |